Companies › Supergene
1 active drug program in 3 registered trials: 3 Phase 3; Neurology, Cardiovascular; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Non-immunogenic recombinant staphylokinase (Fortelyzin®) Staphylokinase, a plasminogen activator | PLG, PLMN | Phase 3 | Acute Limb Ischemia; Pulmonary Embolism; Ischemic Stroke, Acute | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05372718 | Non-immunogenic recombinant staphylokinase (Fortelyzin®) | Phase 3 | Acute Limb Ischemia | Cardiovascular | Sep 2026 |
| NCT06362746 | Non-immunogenic recombinant staphylokinase (Fortelyzin®) | Phase 3 | Pulmonary Embolism | Cardiovascular | Jun 2028 |
| NCT07324837 | Non-immunogenic recombinant staphylokinase (Fortelyzin®) | Phase 3 | Ischemic Stroke, Acute | Neurology | Nov 2028 |
Ascension Health Jiangsu Jingze Biopharmaceutical Youssef Yammine
Sandoz Neurona Therapeutics Merz Pharmaceuticals Lupin Intellia Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.